Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07265947 · ClinicalTrials.gov registry record · Phase 2
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
A Phase 2 study of Low-grade Upper Tract Urothelial Carcinoma, sponsored by Tyra Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 2
- Study locations
NCT07265947: Recruiting Phase 2 study of Low-grade Upper Tract Urothelial Carcinoma, sponsored by Tyra Biosciences.
NCT07265947 is a Phase 2 study of Low-grade Upper Tract Urothelial Carcinoma that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 230 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07265947, a Phase 2 study of Low-grade Upper Tract Urothelial Carcinoma, is actively recruiting participants, sponsored by Tyra Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Primary Outcome
Complete response (CR) rate
Conditions Studied
Interventions
- DRUG Dabogratinib (TYRA-300) 60mg
- DRUG Dabogratinib (TYRA-300) 80mg
- DRUG Dabogratinib (TYRA-300) TBD
Study Locations (2)
Indiana
- First Urology - Jeffersonville
Tennessee
- Urology Associates, P C - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2030-11 |
| Phase | Phase 2 |
What NCT07265947 shows while recruiting
NCT07265947 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher).
The record links to 1 condition, with Low-grade Upper Tract Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Dabogratinib (TYRA-300) 60mg is the first listed.
NCT07265947 reports a single indexed study location in Indiana, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07265947 about?
NCT07265947 is a clinical study titled "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma". A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
What is the current status of trial NCT07265947?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2025-12-22. Estimated completion is 2030-11.
What conditions does trial NCT07265947 study?
This clinical trial studies the following conditions: Low-grade Upper Tract Urothelial Carcinoma.
What interventions are being tested in trial NCT07265947?
The interventions under investigation include: Dabogratinib (TYRA-300) 60mg (DRUG), Dabogratinib (TYRA-300) 80mg (DRUG), Dabogratinib (TYRA-300) TBD (DRUG).
Who is sponsoring clinical trial NCT07265947?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07265947 being conducted?
This trial has 2 study locations across Indiana, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low-grade Upper Tract Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07265947's enrollment target sits among peer trials
230 257th of 2000 higher than 1,738 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI